SM
NBSE

Salzhauer Michael’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Salzhauer Michael’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-47
Closed -$35K – 170
2017
Q4 		$35K Sell
47
-42
-47% -$16.2K 0.01% 162
2017
Q3 		$26K Hold
89
– – 0.01% 161
2017
Q2 		$23K Buy
+89
New +$23.9K 0.01% 160

Other funds holding NBSE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Salzhauer Michael's NBSE Position: Q1 2018 in Review

Salzhauer Michael sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2018, closing a stake of 47 shares — an estimated $35K sold.

Salzhauer Michael first reported a position in NBSE in Q2 2017 and held it in 3 quarters. The position peaked at $35K in Q4 2017. 35 funds tracked by Wall St. Rank hold NBSE as of Q1 2018.

  • Salzhauer Michael reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Salzhauer Michael sold 47 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $35K.
  • Salzhauer Michael first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2017 and held it in 3 quarters.
  • Salzhauer Michael's NeuBase Therapeutics, Inc. Common Stock position peaked at $35K in Q4 2017.
  • 35 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Salzhauer Michael's 13F filing for Q1 2018, filed 4 May 2018.